

GenCore version 4.5  
Copyright (c) 1993 - 2000 CompuGen Ltd

OM protein - protein search, using sw model

Run on: August 14, 2002, 09:40:13 ; Search time 30.46 Seconds  
(without alignments)  
466.758 Million cell updates/sec

Title: US-09-684-215A-18

Percent score: 83  
Sequence: 1 TAAADNFQLSQGGGFAPI.....QTKSGGTRGNVTLAEGPPA 128

Scoring table: BLOSUM62

Searched: 747574 seqs, 111073796 residues

Total number of hits satisfying chosen parameters: 747574

```
Minimum DB seq length: 0
Maximum DB seq length: 20000000000
```

```

Post-processing:  Minimum Match 0%
                  Maximum Match 100%
                  Listing first 45 summaries

```

Database :

```
A_Geneseq_033802:*
1: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1980.DAT.*
2: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1981.DAT.*
3: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1982.DAT.*
4: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1983.DAT.*
5: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1984.DAT.*
6: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1985.DAT.*
7: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1986.DAT.*
8: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1987.DAT.*
9: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1988.DAT.*
10: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1989.DAT.*
11: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1990.DAT.*
12: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1991.DAT.*
13: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1992.DAT.*
14: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1993.DAT.*
15: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1994.DAT.*
16: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1995.DAT.*
17: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1996.DAT.*
18: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1997.DAT.*
19: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1998.DAT.*
20: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA1999.DAT.*
21: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA2000.DAT.*
22: /SDSI/gcgdata/hold-geneseq/geneseqp-emb1/AA2001.DAT.*
```

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Query				ID	Description
	Score	Match	Length	DB		
1	653	100.0	224	22	AAU69899	Human prostate prot
2	653	100.0	224	22	AAAM0154	Ra12-P510S-C const
3	653	100.0	304	22	AAU69902	Human /M. tubercul
4	653	100.0	304	22	AAAM0157	Ra12-P775P-ORP3 co
5	653	100.0	400	22	AAU69907	Human prostate pro
6	653	100.0	400	22	AAAM0162	Ra12-P501S-E2 cons
7	653	100.0	487	22	AAAG83280	Chlamydia trachoma
8	653	100.0	518	22	AAAG83276	Chlamydia trachoma
9	653	100.0	525	21	AA813645	C. pneumoniae serot
10	653	100.0	525	22	AAAG83213	Protein encoded by
11	653	100.0	583	22	AAAG83281	Chlamydia trachoma

12	653	100.0	585	22	AAG63277	Chlamydia trachoma
13	653	100.0	619	22	AAG63270	Chlamydia trachoma
14	653	100.0	631	22	AAG63274	Chlamydia trachoma
15	653	100.0	646	22	AAG63272	Chlamydia trachoma
16	653	100.0	654	22	AAG63278	Chlamydia trachoma
17	653	100.0	683	22	AAG63282	Chlamydia trachoma
18	653	100.0	691	22	AAG63271	Chlamydia trachoma
19	653	100.0	700	22	AAG63279	Chlamydia trachoma
20	653	100.0	715	22	AAG63273	Chlamydia trachoma
21	653	100.0	715	22	AAG63275	Chlamydia trachoma
22	632	96.8	231	20	AAV32071	Mycobacterium tube
23	632	96.8	355	20	AAV05000	Mycobacterium spec
24	632	96.8	355	20	AAV05000	Mycobacterium tube
25	632	96.8	379	20	AAV04830	Mycobacterium spec
26	632	96.8	543	22	AAU01905	M. tuberculosis an
27	632	96.8	729	20	AAV32059	Mycobacterium tube
28	627	96.0	132	18	AAW32452	Mycobacterium tube
29	627	96.0	132	18	AAW32354	M. tuberculosis im
30	627	96.0	132	19	AAW61657	Mycobacterium tube
31	627	96.0	132	19	AAW64294	Mycobacterium tube
32	627	96.0	132	20	AAV39096	M. tuberculosis an
33	627	96.0	132	20	AAV38955	M. tuberculosis re
34	627	96.0	132	22	AAU69896	Mycobacterium tube
35	627	96.0	132	22	AAU69896	Mycobacterium tube
36	627	96.0	132	22	AAU01253	Mycobacterium tube
37	627	96.0	132	22	AAU01261	Mycobacterium tube
38	627	96.0	132	22	AAU01889	M. tuberculosis pa
39	627	96.0	355	18	AAW32435	Mycobacterium tube
40	627	96.0	355	18	AAW32367	Mycobacterium tube
41	627	96.0	355	19	AAW61670	M. tuberculosis im
42	627	96.0	355	19	AAW64307	Mycobacterium tube
43	627	96.0	355	20	AAV38109	M. tuberculosis re
44	627	96.0	355	20	AAV38972	M. tuberculosis re
45	627	96.0	355	22	AAU01890	M. tuberculosis an

## ALIGNMENTS

RESULT	1
AAU69899	
ID	AAU69899 standard; Protein; 224 AA.
XX	
AC	AAU69899;
XX	
DT	30-JAN-2002 (first entry)
DE	
XX	Human prostate protein/M. tuberculosis Ra12 fusion protein Ra12-P510S-C
XX	
KW	Human; prostate cancer; cytostatic; immunostimulant; tumour; immunogen; fusion protein.
XX	
OS	Chimeric - Homo sapiens.
OS	Chimeric - Microbacterium tuberculosis.
OS	Synthetic.
XX	
PN	WO200173032-A2.
PD	
XX	
PD	04-OCT-2001.
XX	
Pf	27-MAR-2001; 2001WO-US09919.
XX	
XX	27-MAR-2000; 2000US-0536857.
PR	09-MAY-2000; 2000US-05568100.
PR	12-MAY-2000; 2000US-0570737.
PR	13-JUN-2000; 2000US-0593793.
PR	27-JUN-2000; 2000US-0605783.
PR	10-AUG-2000; 2000US-0636215.
PR	29-AUG-2000; 2000US-0651236.
PR	06-SEP-2000; 2000US-0652279.
PR	02-OCT-2000; 2000US-0679426.
PR	10-OCT-2000; 2000US-0685166.
XX	

PA (CORI-) CORIXA CORP.

XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;  
PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedvick TS, Carter D;  
PI Li SX, Wang A, Skelky YAW, Hepler WT, Henderson RA;  
XX WPI; 2001-639232/73.  
DR N-PSDB; AAS64132.

XX New human prostate-specific polypeptides and polynucleotides useful for  
PT the diagnosis and treatment of cancer, especially prostate cancer -  
PS Example 17; Page 533-534; 579pp; English.

XX The invention relates to isolated prostate-specific  
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,  
CC antibodies raised against the polypeptides (or antigenic epitopes  
CC derived from them) and antigen-presenting cells expressing the  
CC polypeptides. The antibodies are useful for detecting the presence of  
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and  
CC T cells specific for a tumour protein, and for stimulating and/or expanding  
CC of cancer especially prostate cancer. Compositions comprising the  
CC polynucleotide and/or polypeptide are useful for stimulating an immune  
CC response, and for treating cancer. The oligonucleotide is useful for  
CC detecting cancer. The present sequence is fusion protein comprising a  
CC prostate specific polypeptide of the invention.

XX Sequence 224 AA;

Query Match 100.0%; Score 653; DB 22; Length 224;  
Best Local Similarity 100.0%; Pred. No. 1.2e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFQLSOGGQGFAPIGQAMAIAGQIKLPVHIGPTAFGLGVVNDNGNGARVQRV 60

Db 8 taasdnfqlsogggqgfaiipigqamaiaqiklpvhiptafglgvvndngngarvqr 67

QY 61 VGSAPASLIGSTGDIVTAVDGAIPINSATAMADALNGHHPGDVISVTWQTKSGGTRTGNV 120

Db 68 vgsapaasligstgdivltavdgapinsatamadalinghpgdivsvtwtksggtrtgnv 127

QY 121 TLAEGPPA 128

Db 128 tlaegppa 135

RESULT 2

AA01254  
ID AAM01254 standard; protein; 224 AA.

XX AAM01254;

XX 04-OCT-2001 (first entry)

XX Ral2-P510S-C construct amino acid sequence.

XX Human; prostate cancer; prostate-specific; diagnosis; vaccine;  
KW cytosolic; gene therapy; metastasis.

XX Homo sapiens.

XX WO200151633-A2.

XX 19-JUL-2001.

XX 16-JAN-2001; 2001WO-US01574.

XX 14-JAN-2000; 2000US-0483672.

XX (CORI-) CORIXA CORP.

PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;  
PI Kalos MD, Fanger GR, Day CH, Retter MW, Stolk JA, Skelky YAW;  
PI Wang A, Meagher MJ;  
XX WPI; 2001-425873/45.

XX New polynucleotide encoding a prostate-specific protein, for  
PT diagnosing, monitoring and treating prostate cancer in a patient and  
PT for use in vaccines -  
PS Claim 8; Page 493-494; 543pp; English.

XX The present invention describes polynucleotide sequences (I) which encode  
CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,  
CC and can be used in vaccine production and gene therapy. (I), (II),  
CC antibodies to (II), fusion proteins comprising (II), and isolated  
CC T cells prepared using (I) or (II) are used treat cancer in a patient.  
CC (I) and the antibodies are also used in the detection of cancer in a  
CC patient. The cancer that is diagnosed or treated is particularly  
CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or  
CC (I) can be used for monitoring the progression of cancer in a patient.  
CC (I) and (II) can also be used to improve diagnostic and therapeutic  
CC methods for prostate cancer. They can indicate the level of metastasis  
CC as well as the prostate volume. AAH93357 to AAH93944 and AAM01115 to  
CC AAM01318 represent polynucleotide and amino acid sequences used in the  
CC exemplification of the present invention.

XX Sequence 224 AA;

Query Match 100.0%; Score 653; DB 22; Length 224;  
Best Local Similarity 100.0%; Pred. No. 1.2e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFQLSOGGQGFAPIGQAMAIAGQIKLPVHIGPTAFGLGVVNDNGNGARVQRV 60

Db 8 taasdnfqlsogggqgfaiipigqamaiaqiklpvhiptafglgvvndngngarvqr 67

QY 61 VGSAPASLIGSTGDIVTAVDGAIPINSATAMADALNGHHPGDVISVTWQTKSGGTRTGNV 120

Db 68 vgsapaasligstgdivltavdgapinsatamadalinghpgdivsvtwtksggtrtgnv 127

QY 121 TLAEGPPA 128

Db 128 tlaegppa 135

RESULT 3

AA069902  
ID AA069902 standard; Protein; 304 AA.

XX AA069902;

XX 30-JAN-2002 (first entry)

XX Human /M. tuberculosis Ral2 fusion protein Ral2-P775P-ORF3.

XX Human; prostate cancer; cytosolic; immunostimulant; tumour; immunogen;  
KW fusion protein.

XX Chimeric - Homo sapiens.

XX Chimeric - Microbacterium tuberculosis.

XX Synthetic.

XX WO200173032-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09919.

XX 27-MAR-2000; 2000US-0536857.

XX 09-MAY-2000; 2000US-0568100.

XX 12-MAY-2000; 2000US-0570737.

PR 13-JUN-2000; 2000US-0593793.  
PR 27-JUN-2000; 2000US-0605783.  
PR 10-AUG-2000; 2000US-0636215.  
PR 29-AUG-2000; 2000US-0651236.  
PR 06-SEP-2000; 2000US-0657279.  
PR 02-OCT-2000; 2000US-0679426.  
PR 10-OCT-2000; 2000US-0685166.

XX (CORI-) CORIXA CORP.

XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;  
PI Fanger GR, Retter MW, Stoik JA, Day CH, Vedvick TS, Carter D;  
PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;

XX WPI: 2001-639232/773.  
DR N-PDSB; AAS64141.

PT New human prostate-specific polypeptides and polynucleotides useful for  
PT the diagnosis and treatment of cancer, especially prostate cancer -  
XX  
XX Example 17; Page 537; 579pp; English.

CC The invention relates to isolated prostate-specific  
CC polynucleotides, polypeptides, fusion proteins of the polypeptides,  
CC antibodies raised against the polypeptides (or antigenic epitopes  
CC derived from them) and antigen-presenting cells expressing the  
CC polypeptides. The antibodies are useful for detecting the presence of  
CC cancer, especially prostate cancer. The polypeptides, polynucleotides and  
CC the antigen-presenting cells are useful for stimulating and/or expanding  
CC T cells specific for a tumour protein, and for inhibiting the development  
CC of cancer especially prostate cancer. Compositions comprising the  
CC polynucleotide and/or polypeptide are useful for stimulating an immune  
CC response, and for treating cancer. The oligonucleotide is useful for  
CC detecting cancer. The present sequence is fusion protein comprising a  
CC prostate specific polypeptide of the invention.

XX Sequence 304 AA;

Query Match 100.0%; Score 653; DB 22; Length 304;

Best Local Similarity 100.0%; Pred. No. 1.8e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAAADNFQLSOGGQGFALPIGQAMAIAGQIKLPYHIGPTAFGLGVNDNGCARVORY 60

DB 8 taasdnfqlsggggfaipigqamalaagqiklpvnhgptafglgvndngcarvory 67

OY 61 VGSAPAAASIGISTGDIYTVAVDGAIPINSATAMADALNGHHGDIYSVTWQTKSGSTRGNV 120

DB 68 vgsapaasigistgdvltavdgapinsatamadalnghhpgdvistwqtksgstrtnv 127

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

PD 19-JUL-2001.

XX 16-JAN-2001; 2001WO-US01574.

XX 14-JAN-2000; 2000US-0483672.

XX (CORI-) CORIXA CORP.

XX Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;  
PI Kalos MD, Fanger GR, Day CH, Retter MW, Stoik JA, Skeiky YAW;  
PI Wang A, Meagher MJ;

XX WPI: 2001-425873/45.

PT New polynucleotide encoding a prostate-specific protein, for  
PT diagnosing, monitoring and treating prostate cancer in a patient and  
PT for use in vaccines -  
XX  
XX Claim 8; Page 498-499; 543pp; English.

CC The present invention describes polynucleotide sequences (I) which encode  
CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,  
CC and can be used in vaccine production and gene therapy. (I), (II),  
CC antibodies to (II), fusion proteins comprising (II), and isolated  
CC T cells prepared using (I) or (II) are used to treat cancer in a patient.  
CC (I) and the antibodies are also used in the detection of cancer in a  
CC patient. The cancer that is diagnosed or treated is particularly  
CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or  
CC (I) can be used for monitoring the progression of cancer in a patient.  
CC (I) and (II) can also be used to improve diagnostic and therapeutic  
CC methods for prostate cancer. They can indicate the level of metastasis  
CC as well as the prostate volume. AAH93357 to AAH93944 and AAH01115 to  
CC AAH01318 represent polynucleotide and amino acid sequences used in the  
CC exemplification of the present invention.

XX Sequence 304 AA;

Query Match 100.0%; Score 653; DB 22; Length 304;

Best Local Similarity 100.0%; Pred. No. 1.8e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAAADNFQLSOGGQGFALPIGQAMAIAGQIKLPYHIGPTAFGLGVNDNGCARVORY 60

DB 8 taasdnfqlsggggfaipigqamalaagqiklpvnhgptafglgvndngcarvory 67

OY 61 VGSAPAAASIGISTGDIYTVAVDGAIPINSATAMADALNGHHGDIYSVTWQTKSGSTRGNV 120

DB 68 vgsapaasigistgdvltavdgapinsatamadalnghhpgdvistwqtksgstrtnv 127

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

OY 121 TLAEGPPA 128

DB 128 tlaegppa 135

RESULT 5

AAU69907 standard; protein; 400 AA.

XX AAU69907;

XX 30-JAN-2002 (first entry)

XX Human prostate protein/M. tuberculosis Ral2 fusion protein Ral2-P50L5-E2.

XX Human prostate cancer; cytostatic; immunostimulant; tumour; immunogen;

XX fusion protein.

XX Chimeric - Homo sapiens.

XX Chimeric - Microbacterium tuberculosis.

XX WO200173032-A2.

XX

XX

XX

XX

PD 04-OCT-2001.  
 XX  
 PF 27-MAR-2001; 2001WO-US09919.  
 XX  
 XX 27-MAR-2000; 2000US-0536857.  
 PR 09-MAY-2000; 2000US-0568100.  
 PR 12-MAY-2000; 2000US-0570737.  
 PR 13-JUN-2000; 2000US-0593793.  
 PR 27-JUN-2000; 2000US-0605783.  
 PR 10-AUG-2000; 2000US-0636215.  
 PR 29-AUG-2000; 2000US-0651236.  
 PR 06-SEP-2000; 2000US-0657279.  
 PR 02-OCT-2000; 2000US-0679426.  
 PR 10-OCT-2000; 2000US-0685166.  
 XX  
 PA (CORI-) CORIXA CORP.  
 XX  
 PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Kalos MD;  
 PI Fanger GR, Retter MW, Stolk JA, Day CH, Vedvick TS, Carter D;  
 PI Li SX, Wang A, Skeiky YAW, Hepler WT, Henderson RA;  
 XX  
 DR WPI: 2001-639232/73.  
 DR N-PSDB; AAS64153.  
 XX  
 PT New human prostate-specific polypeptides and polynucleotides useful for  
 PT the diagnosis and treatment of cancer, especially prostate cancer -  
 XX  
 XX Example 17; Page 543-544; 579pp; English.  
 XX  
 PS The invention relates to isolated prostate-specific  
 CC polynucleotides, polypeptides, fusion proteins of the polypeptides,  
 CC antibodies raised against the polypeptides (or antigenic epitopes  
 CC derived from them) and antigen-presenting cells expressing the  
 CC polypeptides. The antibodies are useful for detecting the presence of  
 CC cancer, especially prostate cancer. The polypeptides, polynucleotides and  
 CC T cells specific for a tumor protein, and for inhibiting the development  
 CC of cancer especially prostate cancer. Compositions comprising the  
 CC polynucleotide and/or polypeptide are useful for stimulating an immune  
 CC response, and for treating cancer. The oligonucleotide is useful for  
 CC detecting cancer. The present sequence is fusion protein comprising a  
 CC prostate specific polypeptide of the invention.  
 CC  
 XX  
 SQ Sequence 400 AA;  
 Query Match 100.0%; Score 653; DB 22; Length 400;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TAASDNFQLSGGGGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVVDNNGNGARVQRV 60  
 Db 8 taasdnfqlsggggfaipigqamaiaqiklpvhiptafglgvvdnngngarvqr 67  
 QY 61 VGSAPASLIGISTGDTVITAVDGAIPINSATAMADALNGHHPEVDVSYVMQTSGGTRGNV 120  
 Db 68 vgsapasligistgdtvitavdgapinsatamadalnghhpgdivsvtwqtksgtrtgnv 127  
 QY 121 TLAEGPPA 128  
 Db 128 tlaegppa 135

RESULT 6  
 AAM01262  
 ID AAM01262 standard; Protein; 400 AA.  
 AC AAM01262;  
 XX  
 XX 04-OCT-2001 (first entry)  
 DE Ral2-P501S-E2 construct amino acid sequence.

4

KW Human: prostate cancer: prostate-specific; diagnosis; vaccine;  
 KW cytostatic; gene therapy; metastasis.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200151633-A2.  
 XX  
 PD 19-JUL-2001.  
 XX  
 PF 16-JAN-2001; 2001WO-US01574.  
 XX  
 PR 14-JAN-2000; 2000US-0483672.  
 XX  
 PA (CORI-) CORIXA CORP.  
 XX  
 PI Xu J, Dillon DC, Mitcham JL, Harlocker SL, Jiang Y, Reed SG;  
 PI Kalos MD, Fanger GR, Day CH, Retter MW, Stolk JA, Skeiky YAW;  
 PI Wang A, Meagher MJ;  
 XX  
 DR WPI: 2001-425873/45.  
 XX  
 PT New polynucleotide encoding a prostate-specific protein, for  
 PT diagnosing, monitoring and treating prostate cancer in a patient and  
 PT for use in vaccines -  
 XX  
 PS Claim 8; Page 504-506; 543pp; English.  
 XX  
 CC The present invention describes polynucleotide sequences (I) which encode  
 CC prostate-specific proteins (II). (I) and (II) have cytostatic activity,  
 CC and can be used in vaccine production and gene therapy. (I), (II),  
 CC antibodies to (I), fusion proteins comprising (II), and isolated  
 CC T cells prepared using (I) or (II) are used treat cancer in a patient.  
 CC (I) and the antibodies are also used in the detection of cancer in a  
 CC patient. The cancer that is diagnosed or treated is particularly  
 CC prostate cancer. (I) and (II) can be used in vaccines. The antibodies or  
 CC (I) can be used for monitoring the progression of cancer in a patient.  
 CC (I) and (II) can also be used to improve diagnostic and therapeutic  
 CC methods for prostate cancer. They can indicate the level of metastasis  
 CC as well as the prostate volume. AAH93357 to AAH93944 and AAM01115 to  
 CC AAM01318 represent polynucleotide and amino acid sequences used in the  
 CC exemplification of the present invention.  
 CC  
 XX  
 SQ Sequence 400 AA;  
 Query Match 100.0%; Score 653; DB 22; Length 400;  
 Best Local Similarity 100.0%; Pred. No. 2.5e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TAASDNFQLSGGGGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVVDNNGNGARVQRV 60  
 Db 8 taasdnfqlsggggfaipigqamaiaqiklpvhiptafglgvvdnngngarvqr 67  
 QY 61 VGSAPASLIGISTGDTVITAVDGAIPINSATAMADALNGHHPEVDVSYVMQTSGGTRGNV 120  
 Db 68 vgsapasligistgdtvitavdgapinsatamadalnghhpgdivsvtwqtksgtrtgnv 127  
 QY 121 TLAEGPPA 128  
 Db 128 tlaegppa 135

RESULT 7  
 AAG83280  
 ID AAG83280 standard; Protein; 487 AA.  
 AC AAG83280;  
 XX  
 XX 05-SEP-2001 (first entry)  
 DE Chlamydia trachomatis PmpC(1) fusion protein.  
 XX  
 XX Chlamydia; vaccine; infection; fusion protein; antigen;  
 KW

KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
 KM acute respiratory tract infection; Cap1; CT529; OMCB;  
 XX polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
 XX Chlamydia trachomatis.  
 OS  
 PN WO200140474-A2.  
 XX  
 PD 07-JUN-2001.  
 XX  
 PF 04-DEC-2000; 2000WO-US32919.  
 XX  
 PR 03-DEC-1999; 99US-0454684.  
 PR 19-APR-2000; 2000US-0556877.  
 PR 20-JUN-2000; 2000US-0598419.  
 XX  
 PA (CORI-) CORIXA CORP.  
 XX  
 PI Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;  
 XX  
 DR WPI; 2001-374831/39.  
 XX  
 PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic  
 PT inflammatory disease, trachoma, acute respiratory tract infections,  
 PT atherosclerosis and heart disease -  
 XX  
 PS Claim 70; Page 289-290; 295pp; English.  
 XX  
 CC The present sequence is provided in a specification relating to  
 CC compounds and methods for the treatment and diagnosis of chlamydial  
 CC infection. The compounds provided include polypeptides and fusion  
 CC proteins comprising immunogenic portions of Chlamydia antigens  
 CC and DNA sequences encoding such polypeptides. They are useful for  
 CC vaccinating against chlamydial infection, which causes pelvic  
 CC inflammatory disease, trachoma, acute respiratory tract infections,  
 CC atherosclerosis and heart disease.  
 CC  
 XX  
 SQ Sequence 487 AA:  
 XX  
 Query Match 100.0%; Score 653; DB 22; Length 487;  
 Best Local Similarity 100.0%; Pred. No. 3.2e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TAASDNFQLSGGGGFAIPRIGQAMAIAGQIKLPVHIGTFAFLGICVVDNNGARVQRV 60  
 DB 8 taasdnfqlsggggfaiprigamaiaqiklpvhiptatflgylvvdmngarvqr 67  
 QY 61 VGSAPAAASIGISTGVITAVDGPAPINSATAMADALNGHHPGDIYSVTWOTKSGGRTGNV 120  
 DB 68 vgsapaasigistgditavdgapinsatamadalinghpgdvisvtwtksggtrtgnv 127  
 QY 121 TLAEGPPA 128  
 DB 128 tlaegppa 135

RESULT 8  
 AAG83276  
 ID AAG83276 standard; Protein; 518 AA.  
 XX  
 AC AAG83276;  
 XX  
 DT 05-SEP-2001 (first entry)  
 XX  
 DE Chlamydia trachomatis PmpB(1) fusion protein.  
 XX  
 KM Chlamydia; vaccine; infection; fusion protein; antigen;  
 KM pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
 KM acute respiratory tract infection; Cap1; CT529; OMCB;  
 KM polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
 XX  
 OS Chlamydia trachomatis.

XX  
 PN WO200140474-A2.  
 XX  
 PD 07-JUN-2001.  
 XX  
 PF 04-DEC-2000; 2000WO-US32919.  
 XX  
 PR 03-DEC-1999; 99US-0454684.  
 PR 19-APR-2000; 2000US-0556877.  
 PR 20-JUN-2000; 2000US-0598419.  
 XX  
 PA (CORI-) CORIXA CORP.  
 XX  
 PI Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;  
 XX  
 DR WPI; 2001-374831/39.  
 XX  
 PT Chlamydia polypeptides and fusion proteins useful for preventing pelvic  
 PT inflammatory disease, trachoma, acute respiratory tract infections,  
 PT atherosclerosis and heart disease -  
 XX  
 PS Claim 70; Page 279-280; 295pp; English.  
 XX  
 CC The present sequence is provided in a specification relating to  
 CC compounds and methods for the treatment and diagnosis of chlamydial  
 CC infection. The compounds provided include polypeptides and fusion  
 CC proteins comprising immunogenic portions of Chlamydia antigens  
 CC and DNA sequences encoding such polypeptides. They are useful for  
 CC vaccinating against chlamydial infection, which causes pelvic  
 CC inflammatory disease, trachoma, acute respiratory tract infections,  
 CC atherosclerosis and heart disease.  
 CC  
 XX  
 SQ Sequence 518 AA:  
 XX  
 Query Match 100.0%; Score 653; DB 22; Length 518;  
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 TAASDNFQLSGGGGFAIPRIGQAMAIAGQIKLPVHIGTFAFLGICVVDNNGARVQRV 60  
 DB 8 taasdnfqlsggggfaiprigamaiaqiklpvhiptatflgylvvdmngarvqr 67  
 QY 61 VGSAPAAASIGISTGVITAVDGPAPINSATAMADALNGHHPGDIYSVTWOTKSGGRTGNV 120  
 DB 68 vgsapaasigistgditavdgapinsatamadalinghpgdvisvtwtksggtrtgnv 127  
 QY 121 TLAEGPPA 128  
 DB 128 tlaegppa 135

RESULT 9  
 AAB13645  
 ID AAB13645 standard; Protein; 525 AA.  
 XX  
 AC AAB13645;  
 XX  
 DT 02-FEB-2001 (first entry)  
 XX  
 DE C. pneumoniae serovar WOMPS pmp gene Ra12 fusion protein.  
 XX  
 KM Chlamydial infection; sexually transmitted disease;  
 KM pelvic inflammatory disease; PID; tubal obstruction; infertility;  
 KM trachoma; blindness; acute respiratory tract infection;  
 KM atherosclerosis; coronary heart disease; antibacterial.  
 XX  
 OS Chlamydia pneumoniae.  
 XX  
 PN WO200034483-A2.  
 XX  
 PD 15-JUN-2000.

PF 08-DEC-1999; 99WO-US29012.  
 XX  
 PR 08-DEC-1998; 98US-0208277.  
 PR 08-APR-1999; 99US-0288594.  
 PR 01-OCT-1999; 99US-0410568.  
 PR 22-OCT-1999; 99US-0426571.  
 XX  
 PA (CORI-) CORIXA CORP.

PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Jen S, Stromberg EJ;  
 XX WPL; 2000-431303/37.  
 DR

XX Isolated polypeptide for diagnosis and treatment of Chlamydia infection  
 PT comprises immunogenic portion of Chlamydia antigen, which comprises  
 PR amino acid sequence encoded by polynucleotide sequence -  
 XX

PS Claim 2; Pages 221-222; 256pp; English.

CC The present invention relates to new nucleic acid sequences and the  
 CC proteins encoded by the nucleic acid sequences. The encoded proteins  
 CC comprise an immunogenic portion of a Chlamydia antigen. The encoded  
 CC proteins are useful for the serodiagnosis and treatment of Chlamydia  
 CC infection. Chlamydiae are intracellular bacterial pathogens that are  
 CC responsible for a wide variety of human infections. C. trachomatis  
 CC infection is one of the most common sexually transmitted diseases and can  
 CC lead to pelvic inflammatory disease (PID), resulting in tubal obstruction  
 CC and infertility. Trachoma due to ocular infection with C. trachomatis is  
 CC the leading cause of preventable blindness worldwide. C. pneumoniae is a  
 CC major cause of acute respiratory tract infections in humans and is also  
 CC thought to play a role in the pathogenesis of atherosclerosis and  
 CC coronary heart disease. The present sequence is a protein isolated in the  
 CC present invention.  
 CC  
 XX Sequence 525 AA;  
 SQ

Query Match 100.0%; Score 653; DB 21; Length 525;  
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGGFAIPIGQAMAIAGQIKLPVTHIGPTAFGLGVVDNNGGARVORV 60  
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 8 taasdnfqlsgggfaiplvgamaiaqgiklprvthigptaflgvgvndngngarvgrv 67  
 QY 61 VGSAPAAASLGISTGDTVITAVDGAIPINSATAMADALNGHHHPGDIVISVTWOTKSGGTRTGNV 120  
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 68 vgsapaaslgistgdtvitavdgapinsatamadalinghpgdivisvtwqtksggtrtgnv 127  
 QY 121 TLAEGPPA 128  
 DB ||||||||  
 128 tlaegppa 135

RESULT 10  
 AAG83213  
 ID AAG83213 standard; Protein; 525 AA.  
 AC  
 XX AAG83213;  
 AC

DT 05-SEP-2001 (first entry)

XX Protein encoded by Chlamydia trachomatis serovar MOMPS pmp gene.  
 DE

XX Chlamydia; vaccine; infection; fusion protein; antigen;  
 KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
 KW acute respiratory tract infection; Cap1; CT529; OMCB;  
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
 XX Chlamydia trachomatis.  
 OS  
 XX WO200140474-A2.  
 PN  
 XX

PD 07-JUN-2001.

XX 04-DEC-2000; 2000WO-US32919.  
 XX  
 PF 03-DEC-1999; 99US-0454684.  
 PR 19-APR-2000; 2000US-0556877.  
 PR 20-JUN-2000; 2000US-0598419.  
 XX  
 PA (CORI-) CORIXA CORP.

PI Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;  
 XX WPL; 2001-374831/39.  
 DR

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic  
 PT inflammatory disease, trachoma, acute respiratory tract infections,  
 PR atherosclerosis and heart disease -  
 XX

PS Claim 2; Page 226-227; 295pp; English.

CC The present sequence is provided in a specification relating to  
 CC compounds and methods for the treatment and diagnosis of chlamydial  
 CC infection. The compounds provided include polypeptides and fusion  
 CC proteins comprising immunogenic portions of Chlamydia antigens  
 CC and DNA sequences encoding such polypeptides. They are useful for  
 CC vaccinating against chlamydial infection, which causes pelvic  
 CC inflammatory disease, trachoma, acute respiratory tract infections,  
 CC atherosclerosis and heart disease.  
 CC  
 XX Sequence 525 AA;  
 SQ

Query Match 100.0%; Score 653; DB 22; Length 525;  
 Best Local Similarity 100.0%; Pred. No. 3.5e-60;  
 Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TAASDNFOLSGGGFAIPIGQAMAIAGQIKLPVTHIGPTAFGLGVVDNNGGARVORV 60  
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 8 taasdnfqlsgggfaiplvgamaiaqgiklprvthigptaflgvgvndngngarvgrv 67  
 QY 61 VGSAPAAASLGISTGDTVITAVDGAIPINSATAMADALNGHHHPGDIVISVTWOTKSGGTRTGNV 120  
 DB ||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
 68 vgsapaaslgistgdtvitavdgapinsatamadalinghpgdivisvtwqtksggtrtgnv 127  
 QY 121 TLAEGPPA 128  
 DB ||||||||  
 128 tlaegppa 135

RESULT 11  
 AAG83281  
 ID AAG83281 standard; Protein; 583 AA.  
 AC  
 XX AAG83281;  
 AC

DT 05-SEP-2001 (first entry)

XX Chlamydia trachomatis PmpC(2) fusion protein.  
 DE

XX Chlamydia; vaccine; infection; fusion protein; antigen;  
 KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
 KW acute respiratory tract infection; Cap1; CT529; OMCB;  
 KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
 XX Chlamydia trachomatis.  
 OS  
 XX WO200140474-A2.  
 PN  
 XX

PD 07-JUN-2001.

XX 04-DEC-2000; 2000WO-US32919.  
 PF  
 XX 03-DEC-1999; 99US-0454684.  
 PR

PR 19-APR-2000; 2000US-0556877.  
PR 20-JUN-2000; 2000US-0598419.  
XX  
PA (CORI-) CORIXA CORP.  
PI Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;  
XX WPI; 2001-374831/39.  
DR  
XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic  
PT inflammatory disease, trachoma, acute respiratory tract infections,  
PT atherosclerosis and heart disease -  
XX  
XX  
PS Claim 70; Page 291-292; 295pp; English.  
XX  
CC The present sequence is provided in a specification relating to  
CC compounds and methods for the treatment and diagnosis of chlamydial  
CC infection. The compounds provided include polypeptides and fusion  
CC proteins comprising immunogenic portions of Chlamydia antigens  
CC and DNA sequences encoding such polypeptides. They are useful for  
CC vaccinating against chlamydial infection, which causes pelvic  
CC inflammatory disease, trachoma, acute respiratory tract infections,  
CC atherosclerosis and heart disease.  
XX  
SQ Sequence 583 AA;

Query Match 100.0%; Score 653; DB 22; Length 583;  
Best Local Similarity 100.0%; Pred. No. 4e-60;  
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVDNNGARVQRY 60  
Db 8 taasdnfqlsgggqgfalpigamaiaqgiklpvhlqptalflyvvdmngngarvqr 67  
OY 61 VGSAPAAISGISTGVITFVDCAPINSATAMADALNGHHPGDIVSVTWQTKSGGRTGNV 120  
Db 68 vgsapaaslgistgvtlavdgapinsatamadalinghnpdvsvtwqtksggrrtgnv 127

OY 121 TLAEGPPA 128  
Db 128 tlaegppa 135

RESULT 12  
AAG83277  
ID AAG83277 standard; Protein; 585 AA.

AC AAG83277;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpB(2) fusion protein.

XX  
KW Chlamydia: vaccine; infection; fusion protein; antigen;  
KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
KW acute respiratory tract infection; Cap1; CT529; OMCB;  
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
XX  
OS Chlamydia trachomatis.

XX  
PN WO200140474-A2.

PD 07-JUN-2001.

PF 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX  
PA (CORI-) CORIXA CORP.

PI Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;  
XX  
DR WPI; 2001-374831/39.  
XX  
XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic  
PT inflammatory disease, trachoma, acute respiratory tract infections,  
PT atherosclerosis and heart disease -  
XX  
XX  
PS Claim 70; Page 282-283; 295pp; English.  
XX  
CC The present sequence is provided in a specification relating to  
CC compounds and methods for the treatment and diagnosis of chlamydial  
CC infection. The compounds provided include polypeptides and fusion  
CC proteins comprising immunogenic portions of Chlamydia antigens  
CC and DNA sequences encoding such polypeptides. They are useful for  
CC vaccinating against chlamydial infection, which causes pelvic  
CC inflammatory disease, trachoma, acute respiratory tract infections,  
CC atherosclerosis and heart disease.  
XX  
SQ Sequence 585 AA;

Query Match 100.0%; Score 653; DB 22; Length 585;  
Best Local Similarity 100.0%; Pred. No. 4.1e-60;  
Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGQIKLPVHIGPTAFGLGVDNNGARVQRY 60  
Db 8 taasdnfqlsgggqgfalpigamaiaqgiklpvhlqptalflyvvdmngngarvqr 67  
OY 61 VGSAPAAISGISTGVITFVDCAPINSATAMADALNGHHPGDIVSVTWQTKSGGRTGNV 120  
Db 68 vgsapaaslgistgvtlavdgapinsatamadalinghnpdvsvtwqtksggrrtgnv 127

OY 121 TLAEGPPA 128  
Db 128 tlaegppa 135

RESULT 13  
AAG83270  
ID AAG83270 standard; Protein; 619 AA.

AC AAG83270;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpA(N-term) fusion protein.

XX  
KW Chlamydia: vaccine; infection; fusion protein; antigen;  
KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
KW acute respiratory tract infection; Cap1; CT529; OMCB;  
KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
XX  
OS Chlamydia trachomatis.

XX  
PN WO200140474-A2.

PD 07-JUN-2001.

PF 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX  
PA (CORI-) CORIXA CORP.

XX  
PI Probst P, Bhatia A, Skeiky YAM, Fling SP, Scholler J;

DR WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

CC compounds and methods for the treatment and diagnosis of chlamydial  
CC infection. The compounds provided include polypeptides and fusion  
CC proteins comprising immunogenic portions of Chlamydia antigens  
CC and DNA sequences encoding such polypeptides. They are useful for





QY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGGARVQRY 60  
 |||||||  
 Db 8 taasdnfqlsggggfaipigamalaagiklptvhiptafglgvndnggarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120  
 |||||||  
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtksqgtrtgnv 127

OY 121 TLAEGPPA 128  
 |||||||  
 Db 128 tlaegppa 135

## RESULT 18

AAG83271  
 ID AAG83271 standard; Protein: 691 AA.

AC AAG83271;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpA(C-term) fusion protein.

KW Chlamydia; vaccine; infection; fusion protein; antigen;

KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;

KW acute respiratory tract infection; Cap1; CTS29; OMCB;

KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

OS Chlamydia trachomatis.

PN W0200140474-A2.

PD 07-JUN-2001.

PE 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

XX Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;

XX WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

XX inflammatory disease, trachoma, acute respiratory tract infections,

XX atherosclerosis and heart disease -

XX Claim 70; Page 267-268; 295pp; English.

XX The present sequence is provided in a specification relating to

XX compounds and methods for the treatment and diagnosis of chlamydial

XX infection. The compounds provided include polypeptides and fusion

XX proteins comprising immunogenic portions of Chlamydia antigens

XX and DNA sequences encoding such polypeptides. They are useful for

XX vaccinating against chlamydial infection, which causes pelvic

XX inflammatory disease, trachoma, acute respiratory tract infections,

XX atherosclerosis and heart disease.

XX Sequence 691 AA;

Query Match 100.0%; Score 653; DB 22; Length 691;

Best Local Similarity 100.0%; Pred. No. 5e-60; Mismatches 0; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGGARVQRY 60  
 |||||||  
 Db 8 taasdnfqlsggggfaipigamalaagiklptvhiptafglgvndnggarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120  
 |||||||  
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtksqgtrtgnv 127

## RESULT 19

AAG83279  
 ID AAG83279 standard; Protein: 700 AA.

AC AAG83279;

DT 05-SEP-2001 (first entry)

DE Chlamydia trachomatis PmpB(4) fusion protein.

KW Chlamydia; vaccine; infection; fusion protein; antigen;

KW pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;

KW acute respiratory tract infection; Cap1; CTS29; OMCB;

KW polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.

OS Chlamydia trachomatis.

PN W0200140474-A2.

PD 07-JUN-2001.

PE 04-DEC-2000; 2000WO-US32919.

PR 03-DEC-1999; 99US-0454684.

PR 19-APR-2000; 2000US-0556877.

PR 20-JUN-2000; 2000US-0598419.

XX (CORI-) CORIXA CORP.

XX Probst P, Bhatia A, Skelky YAW, Fling SP, Scholler J;

XX WPI; 2001-374831/39.

XX Chlamydia polypeptides and fusion proteins useful for preventing pelvic

XX inflammatory disease, trachoma, acute respiratory tract infections,

XX atherosclerosis and heart disease -

XX Claim 70; Page 286-288; 295pp; English.

XX The present sequence is provided in a specification relating to

XX compounds and methods for the treatment and diagnosis of chlamydial

XX infection. The compounds provided include polypeptides and fusion

XX proteins comprising immunogenic portions of Chlamydia antigens

XX and DNA sequences encoding such polypeptides. They are useful for

XX vaccinating against chlamydial infection, which causes pelvic

XX inflammatory disease, trachoma, acute respiratory tract infections,

XX atherosclerosis and heart disease.

XX Sequence 700 AA;

Query Match 100.0%; Score 653; DB 22; Length 700;

Best Local Similarity 100.0%; Pred. No. 5.1e-60; Mismatches 0; Indels 0; Gaps 0;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TAASDNFOLSGGCGFAIPIGQAMAIAGIKLPTVHIGPTAFGLGVNDNGGARVQRY 60  
 |||||||  
 Db 8 taasdnfqlsggggfaipigamalaagiklptvhiptafglgvndnggarvqr 67

QY 61 VGSAPAAASLGISTGCVITAVDGAIPINSATAMADALNGHHPGDVISVTWQTSGGTRTGNV 120  
 |||||||  
 Db 68 vgsapaaslgistgcvitavdgapinsatamadalinghpgdvlsvtwqtksqgtrtgnv 127

OY 121 TLAEGPPA 128

Job 128 tlaegppa 135

## RESULT 20

AA083273 standard; Protein; 715 AA.

AA083273;

05-SEP-2001 (first entry)

Chlamydia trachomatis PmpF(C-term) fusion protein.

Chlamydia; vaccine; infection; fusion protein; antigen;  
pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
acute respiratory tract infection; Cap1; CT529; OMCB;  
polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
Chlamydia trachomatis.

MO200140474-A2.

07-JUN-2001.

04-DEC-2000; 2000MO-US32919.

03-DEC-1999; 99US-0454684.

19-APR-2000; 2000US-0556877.

20-JUN-2000; 2000US-0598419.

(CORI-) CORIXA CORP.

Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;

MP1; 2001-374831/39.

Chlamydia polypeptides and fusion proteins useful for preventing pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease -

Claim 70; Page 272-273; 295pp: English.

The present sequence is provided in a specification relating to

compounds and methods for the treatment and diagnosis of chlamydial

infection. The compounds provided include polypeptides and fusion

proteins comprising immunogenic portions of Chlamydia antigens

and DNA sequences encoding such polypeptides. They are useful for

vaccinating against chlamydial infection, which causes pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease.

Sequence 715 AA;

Query Match 100.0%; Score 653; DB 22; Length 715;

Best Local Similarity 100.0%; Pred. No. 5.2e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TAAADNFOLSGGOGFAIPIGQAMATAGQIKLPTVHIGPTAFGLGVDDNNGARVORV 60

8 taadnfglsqgggfaipigqamaiaqkllptvhlgrptafglgvyddnngarvgrv 67

61 VGSAPASISIGSTGDIYTAVDGAPINSATAMADALNGHHPGDVISTVWTKSGGTRTGNV 120

68 vgsapaa1s1gstgdiytavdgapinsatamadalinghbgdvisvtwtksggtrtgnv 127

121 TLAEGPPA 128

128 tlaegppa 135

RESULT 21

AA083275 standard; Protein; 715 AA.

AA083275;

05-SEP-2001 (first entry)

Chlamydia trachomatis PmpH(C-term) fusion protein.

Chlamydia; vaccine; infection; fusion protein; antigen;  
pelvic inflammatory disease; trachoma; atherosclerosis; heart disease;  
acute respiratory tract infection; Cap1; CT529; OMCB;  
polymorphic membrane protein; pmp; thiol specific antioxidant; TSA.  
Chlamydia trachomatis.

MO200140474-A2.

07-JUN-2001.

04-DEC-2000; 2000MO-US32919.

03-DEC-1999; 99US-0454684.

19-APR-2000; 2000US-0556877.

20-JUN-2000; 2000US-0598419.

(CORI-) CORIXA CORP.

Probst P, Bhatia A, Skeiky YAW, Fling SP, Scholler J;

MP1; 2001-374831/39.

Chlamydia polypeptides and fusion proteins useful for preventing pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease -

Claim 70; Page 277-278; 295pp: English.

The present sequence is provided in a specification relating to

compounds and methods for the treatment and diagnosis of chlamydial

infection. The compounds provided include polypeptides and fusion

proteins comprising immunogenic portions of Chlamydia antigens

and DNA sequences encoding such polypeptides. They are useful for

vaccinating against chlamydial infection, which causes pelvic

inflammatory disease, trachoma, acute respiratory tract infections,

atherosclerosis and heart disease.

Sequence 715 AA;

Query Match 100.0%; Score 653; DB 22; Length 715;

Best Local Similarity 100.0%; Pred. No. 5.2e-60;

Matches 128; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TAAADNFOLSGGOGFAIPIGQAMATAGQIKLPTVHIGPTAFGLGVDDNNGARVORV 60

8 taadnfglsqgggfaipigqamaiaqkllptvhlgrptafglgvyddnngarvgrv 67

61 VGSAPASISIGSTGDIYTAVDGAPINSATAMADALNGHHPGDVISTVWTKSGGTRTGNV 120

68 vgsapaa1s1gstgdiytavdgapinsatamadalinghbgdvisvtwtksggtrtgnv 127

121 TLAEGPPA 128

128 tlaegppa 135

Search completed: August 14, 2002, 09:40:53  
Job time: 40 sec

Wed Aug 14 09:41:25 2002

us-09-684-215a-18.rag

Page 12